OLYS Pharma: what changed
OLYS Pharma
Largest movements
- Cash -€147,467
down €147,467 (-88.5%), from €166,591 to €19,124
mainly Investment in fixed assets (net) (-€257,205) and Receivables within one year (-€43,615)
- Intangible fixed assets +€106,904
up €106,904 (+12.7%), from €839,861 to €946,765
- Receivables within one year +€43,615
up €43,615 (+243%), from €17,916 to €61,531
of which Trade receivables: +€28,251
- Profit (loss) carried forward +€14,126
up €14,126 (+13.4%), from -€105,533 to -€91,406
- Trade debts -€12,269
down €12,269 (-73.8%), from €16,632 to €4,363
- Gross operating margin -€476,537
down €476,537 (-75.0%), from €634,961 to €158,424
- Depreciation +€61,490
up €61,490 (+68.7%), from €89,446 to €150,936
- Financial charges -€9,999
down €9,999 (-60.6%), from €16,489 to €6,490
- Financial income +€8,553
up €8,553 (+172%), from €4,986 to €13,539
Change in the result, 2024 to 2025
For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.
Derived cash bridge
The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €1,032,748 | €1,034,606 | +€1,858 | +0.2% |
| Formation expenses | 20 | €228 | - | -€228 | |
| Fixed assets | 21/28 | €840,269 | €946,765 | +€106,497 | +12.7% |
| Intangible fixed assets | 21 | €839,861 | €946,765 | +€106,904 | +12.7% |
| Tangible fixed assets | 22/27 | €408 | - | -€408 | |
| Furniture and vehicles | 24 | €408 | - | -€408 | |
| Current assets | 29/58 | €192,252 | €87,841 | -€104,411 | -54.3% |
| Stocks and contracts in progress | 3 | €7,195 | €6,636 | -€560 | -7.8% |
| Stocks | 30/36 | €7,195 | €6,636 | -€560 | -7.8% |
| Amounts receivable within one year | 40/41 | €17,916 | €61,531 | +€43,615 | +243% |
| Trade receivables | 40 | €2,876 | €31,127 | +€28,251 | +982% |
| Other amounts receivable | 41 | €15,039 | €30,404 | +€15,364 | +102% |
| Cash at bank and in hand | 54/58 | €166,591 | €19,124 | -€147,467 | -88.5% |
| Deferred charges and accrued income | 490/1 | €550 | €550 | = | 0.0% |
| Total equity and liabilities | 10/49 | €1,032,748 | €1,034,606 | +€1,858 | +0.2% |
| Equity | 10/15 | €564,848 | €578,974 | +€14,126 | +2.5% |
| Contributions | 10/11 | €496,000 | €496,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€105,533 | -€91,406 | +€14,126 | +13.4% |
| Investment grants | 15 | €174,380 | €174,380 | = | 0.0% |
| Amounts payable | 17/49 | €467,901 | €455,632 | -€12,269 | -2.6% |
| Amounts payable after more than one year | 17 | €200,000 | €200,000 | = | 0.0% |
| Financial debts | 170/4 | €200,000 | €200,000 | = | 0.0% |
| Amounts payable within one year | 42/48 | €267,901 | €255,632 | -€12,269 | -4.6% |
| Trade debts | 44 | €16,632 | €4,363 | -€12,269 | -73.8% |
| Suppliers | 440/4 | €16,632 | €4,363 | -€12,269 | -73.8% |
| Advances received on contracts in progress | 46 | €95 | €95 | = | 0.0% |
| Taxes, remuneration and social security | 45 | €17 | €17 | = | 0.0% |
| Taxes | 450/3 | €17 | €17 | = | 0.0% |
| Other amounts payable | 47/48 | €251,157 | €251,157 | = | 0.0% |
| Remuneration, social security and pensions | 62 | -€20 | - | +€20 | |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €89,446 | €150,936 | +€61,490 | +68.7% |
| Other operating charges | 640/8 | €462 | €411 | -€52 | -11.2% |
| Gross operating margin | 9900 | €634,961 | €158,424 | -€476,537 | -75.0% |
| Operating profit (loss) | 9901 | €545,072 | €7,077 | -€537,996 | -98.7% |
| Financial income | 75/76B | €4,986 | €13,539 | +€8,553 | +172% |
| Recurring financial income | 75 | €4,986 | €13,539 | +€8,553 | +172% |
| Financial charges | 65/66B | €16,489 | €6,490 | -€9,999 | -60.6% |
| Recurring financial charges | 65 | €16,489 | €6,490 | -€9,999 | -60.6% |
| Profit (loss) for the period before taxes | 9903 | €533,570 | €14,126 | -€519,443 | -97.4% |
| Profit (loss) for the period | 9904 | €533,570 | €14,126 | -€519,443 | -97.4% |
| Profit (loss) for the period to be appropriated | 9905 | €533,570 | €14,126 | -€519,443 | -97.4% |
Next steps
Calculation and sources
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. Prepared on 2 November 2026 via checked.be.